Preview

Современная ревматология

Расширенный поиск

Целекоксиб: оценка эффективности и безопасности во втором десятилетии XXI века

https://doi.org/10.14412/1996-7012-2013-2439

Полный текст:

Аннотация

Целекоксиб – эффективный препарат для контроля хронической боли при ревматических заболеваниях. Это единственный нестероидный противовоспалительный препарат, для которого четко доказано снижение частоты осложнений со стороны не только верхних, но и дистальных отделов желудочно-кишечного тракта (ЖКТ), в частности железодефицитной анемии, ассоциированной с патологией тонкой кишки. В реальной клинической практике, отражением которой являются популяционные исследования, целекоксиб относительно редко вызывает кардиоваскулярные осложнения. Хорошая переносимость и низкий риск осложнений со стороны ЖКТ и сердечно-сосудистой системы позволяют успешно применять его в течение длительного времени (при необходимости), не опасаясь развития лекарственных осложнений.

Об авторе

Андрей Евгеньевич Каратеев
ФГБУ «Научно-исследовательский институт ревматологии им. В.А. Насоновой» РАМН, Москва
Россия


Литература

1. <div><p>Боль (практическое руководство для врачей). Под ред. Яхно НН, Кукушкина МЛ. Москва: Издательство РАМН; 2012. 512 c. [Bol' (prakticheskoe rukovodstvo dlya vrachey). Yakhno NN, Kukushkina ML, editors. Moscow: Izdatel'stvo RAMN; 2012. 512 p.]</p><p>McGettigan P, Henry D. Use of non-steroidal anti-inflammatory drugs that elevate cardiovascular risk: an examination of sales and essential medicines lists in low-, middle-, and high-income countries. PLoS Med. 2013;10(2):e1001388. DOI: 10.1371/journal.pmed.1001388. Epub 2013 Feb 12.</p><p>drugs.com [интернет] U.S. Pharmaceutical Sales - 2012 [доступ 02.10.2013]. Available from: http://www.drugs.com/stats/top100/2012/units</p><p>Каратеев АЕ. Использование целекоксиба в ревматологии, кардиологии, неврологии и онкологии. Русский медицинский журнал. 2007;15(22);1660–9. [Karateev AE. Ispol'zovanie tselekoksiba v revmatologii, kardiologii, nevrologii i onkologii. Russkiy meditsinskiy zhurnal. 2007;15(22);1660–9.]</p><p>Patel M, Arber N, Eagle C et al. Celecoxib for the prevention of colorectal adenomatous polyps. N Engl J Med. 2006;355(9):885–95.</p><p>Bertagnolli M, Eagle C, ZauberA et al. Celecoxib for the prevention of sporadic colorectal adenomas. N Engl J Med. 2006;355(9):873–84. DOI: http://dx.doi.org/10.1056%2FNEJMoa061355.</p><p>Koo BK, Km YS, Park KW et al. Effect of celecoxib on restenosis after coronary angioplasty with a Taxus stent (COREA-TAXUS trial): an open-label randomised controlled study. Lancet. 2007;370(9587):567–74.</p><p>Saudan M, Saudan P, Perneger T et al. Celecoxib versus ibuprofen in the prevention of heterotopic ossification following total hip replacement: a prospective randomised trial. J Bone Joint Surg Br. 2007;89(2):155–9. DOI: http://dx.doi.org/10.1302%2F0301-620X.89B2.17747.</p><p>Lyketsos C, Breitner J, Green R et al. Naproxen and celecoxib do not prevent AD in early results from a randomized controlled trial. ADAPT Research Group. Neurology. 2007;68(21):1800–8.</p><p>Cudkowicz M, Shefner J, Schoenfeld D et al. Trial of celecoxib in amyotrophic lateral sclerosis. Ann Neurol. 2006;60(1):22–31. DOI: http://dx.doi.org/10.1002%2Fana.20903.</p><p>Müller N, Krause D, Dehning S et al. Celecoxib treatment in an early stage of schizophrenia: results of a randomized, double-blind, placebo-controlled trial of celecoxib augmentation of amisulpride treatment. Schizophr Res. 2010;121(1-3):118–24. DOI: http://dx.doi.org/10.1016%2Fj.schres.2010.04.015.</p><p>Sommer I, de Witte L, Begemann M, Kahn R. Nonsteroidal anti-inflammatory drugs in schizophrenia: ready for practice or a good start? A meta-analysis. J Clin Psychiatry. 2012;73(04):414–9. DOI: http://dx.doi.org/10.4088%2FJCP.10r06823.</p><p>Malmstrom K, Fricke J, Kotey P et al. A comparison of rofecoxib versus celecoxb in treating pain after dental surgery: a single-center, randomized, double-blind, placebo- and active-comparator-controlled, parallel-group, single-dose study using the dental impaction pain model. Clin Ther. 2002;24(10):1549–60. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2802%2980059-5.</p><p>Cheung R, Krishnaswami S, Kowalski K. Analgesic efficacy of celecoxib in postoperative oral surgery pain: a single-dose, two-center, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2007;29 Suppl:2498–510. DOI: 10.1016/j.clinthera.2007.12.008.</p><p>Gimbel J, Brugger A, Zhao W et al. Efficacy and tolerability of celecoxb versus hydrocodone/acetaminophen in the treatment of pain after ambulatory orthopedic surgery in adults. Clin Ther. 2001;23(2):228–41. DOI: http://dx.doi.org/10.1016%2FS0149-2918%2801%2980005-9.</p><p>Romsing J, Moiniche S. A systematic review of COX-2 inhibitors compared with traditional NSAIDs, or different-2 inhibitors for post-operative pain. Acta Anaesthesiol Scand. 2004;48(5):525–46.</p><p>Chen L, Elliott R, Ascroft D. Systematic review of the analgesic efficacy and tolerability of COX-2 inhibitors in post-operative pain. J Clin Pharm Ther. 2004;29(3):215–29. DOI: http://dx.doi.org/10.1111%2Fj.1365-2710.2004.00558.x.</p><p>Straube S, Derry S, McQuay H, Moore R. Effect of preoperative Cox-II-selective NSAIDs (coxibs) on postoperative outcomes: a systematic review of randomized studies. Acta Anaesthesiol Scand. 2005;49(5):601–13. DOI: http://dx.doi.org/10.1111%2Fj.1399-6576.2005.00666.x.</p><p>Derry S, Moore RA. Single dose oral celecoxib for acute postoperative pain in adults. Cochrane Database Syst Rev. 2012 Mar 14;3:CD004233. DOI: 10.1002/14651858.CD004233.pub3.</p><p>Dietrich I, Ralha L, Chahade W et al. Efficacy and tolerability of celecoxib 200 mg bid ver-sus diclofenac 75 mg bid in acute low back pain. Ann Rheum Dis. 2006;65(Suppl II):238.</p><p>Petri M, Hufman S, Waser G et al. Celecoxib effectively treats patients with acute shoulder tendinitis/bursitis. J Rheumatol. 2004;31:1614–20.</p><p>Schumacher HR, Berger MF, Li-Yu J et al. Efficacy and tolerability of celecoxib in the treatment of acute gouty arthritis: a randomized controlled trial. J Rheumatol. 2012 Sep;39(9):1859-66. DOI: 10.3899/jrheum.110916. Epub 2012 Aug 1.</p><p>O'Donnell J, Ekman E, Spalding W et al. The effectiveness of a weak opioid medication versus a cyclo-oxygenase-2 (COX-2) selective non-steroidal anti-inflammatory drug in treating flare-up of chronic low-back pain: results from two randomized, double-blind, 6-week studies. J Int Med Res. 2009;37(6):1789–802. DOI: http://dx.doi.org/10.1177%2F147323000903700615.</p><p>Zweers M, de Boer T, van Roon J et al. Celecoxib: considerations regarding its potential disease-modifying properties in osteoarthritis. Arthritis Res Ther. 2011;13(5):239. DOI: 10.1186/ar3437. Epub 2011 Sep 21.</p><p>Luyten F, Geusens P, Malaise M et al. A prospective randomised multicentre study comparing continuous and intermittent treatment with celecoxib in patients with osteoarthritis of the knee or hip. Ann Rheum Dis. 2007;66(1):99–106. DOI: http://dx.doi.org/10.1136%2Fard.2006.052308.</p><p>Strand V, Simon L, Dougados M et al. Treatment of osteoarthritis with continuous versus intermittent celecoxib. J Rheumatol. 2011;38(12):2625–34. DOI: http://dx.doi.org/10.3899%2Fjrheum.110636.</p><p>Poddubnyy D, Song I, Sieper J. A systematic comparison of rheumatoid arthritis and ankylosing spondylitis: non-steroidal anti-inflammatory drugs. Clin Exp Rheumatol. 2009;27(4 Suppl 55):S148–51.</p><p>Wanders A, Heijde D, Landewe R et al. Nonsteroidal antiinflammatory drugs reduce radiographic progression in patients with ankylosing spondylitis: a randomized clinical trial. Arthritis Rheum. 2005;52(6):1756–65. DOI: http://dx.doi.org/10.1002%2Fart.21054.</p><p>Silverstein F, Faich G, Goldstein J et al. Gastrointestinal toxicity with celecoxib versus nonsteroidal anti-inflammatory drugs for osteoarthritis and rheumatoid arthritis: the CLASS study: a randomized controlled trial. Celecoxid long-term arthritis safety study. JAMA. 2000;84:1247–55.</p><p>Singh G, Fort J, Goldstein J et al. Celecoxib versus naproxen and diclofenac in osteoarthri-tis patients: SUCCESS-1 study. Am J Med. 2006;119:255–66.</p><p>Moore R, Derry S, Makinson G, McQuay H. Tolerability and adverse events in clinical trials of celecoxib in osteoarthritis and rheumatoid arthritis: systemic review and meta-analysis on information from company clinical reports. Arthritis Res Ther. 2005;7(3):S644–65. Epub 2005 Mar 24.</p><p>Simon L, Weaver A, Graham D. Anti-inflammatory and upper gastrointestinal effects of celecoxib in rheumatoid arthritis: a randomized control trial. JAMA. 1999;282(20);1921–8. DOI: http://dx.doi.org/10.1001%2Fjama.282.20.1921.</p><p>Emery P, Zeidler H, Kvien T et al. Celecoxib versus diclofenac in long-term management of rheumatoid arthritis: randomized double-blind comparison. Lancet. 1999;354:2106–11.</p><p>Каратеев АЕ, Бочкова АГ, Румянцева ОА и др. Применение капсульной эндоскопии для оценки влияния мелоксикама и диклофенака на слизистую оболочку тонкой кишки у больных с анкилозирующим спондилитом: первый опыт. Научно-практическая ревматология. 2011;4:31–5. [Karateev AE, Bochkova AG, Rumyantseva OA и др. Use of capsule endoscopy to evaluate the effects of meloxicam and diclofenac on the small bowel musoca in patients with ankylosing spondylitis: the first experience. Rheumatology Science and Practice. 2011;4:31–5.]</p><p>Davies N, Saleh J, Skjodt N. Detection and prevention of NSAID-induced enteropathy. J Pharm Pharm Sci. 2000;3:137–55.</p><p>Maiden L, Thjodleifsson B, Seigal A et al. Long-term effects of nonsteroidal anti-inflammatory drugs and cyclooxygenase-2 selective agents on the small bowel: a cross-sectional capsule enteroscopy study. Clin Gastroenterol Hepatol. 2007;5(9):1040–5. DOI: http://dx.doi.org/10.1016%2Fj.cgh.2007.04.031 .Epub 2007 Jul 10.</p><p>Sands G, Shell B, Zhang R. Adverse events in patients with blood loss: a pooled analysis of 51 clinical studies from the celecoxib clinical trial database. Open Rheumatol J. 2012;6:44–9.</p><p>Singh G, Agrawal N, Makinson G et al. Safety without borders: upper and lower gastrointestinal safety of celecoxib in a pooled analysis of 52 prospective, randomized, double-blinded, parallel-group clinical trials. EULAR-2010 THU0437.</p><p>Chan F, Lanas A, Scheiman J et al. Celecoxib versus omeprazole and diclofenac in patients with osteoarthritis and rheumatoid arthritis (CONDOR): a randomised trial. Lancet. 2010;376(9736):173–9. DOI: http://dx.doi.org/10.1016%2FS0140-6736%2810%2960673-3.</p><p>Goldstein J, Eisen G, Lewis B et al. Video capsule endoscopy to prospectively assess small bowel injury with celecoxib, naproxen plus omeprazole, and placebo. Clin Gastroenterol Hepatol. 2005;3(2):133–41. DOI: http://dx.doi.org/10.1016%2FS1542-3565%2804%2900619-6.</p><p>Cryer B, Li C, Simon L et al. GI-REASONS: A Novel 6-Month, Prospective, Randomized, Open-Label, Blinded Endpoint (PROBE) Trial. Am J Gastroenterol. 2012;108(3):392–400. DOI: http://dx.doi.org/10.1038%2Fajg.2012.467.</p><p>Castellsague J, Riera-Guardia N, Calingaert B et al. Individual NSAIDs and upper gastrointestinal complications: a systematic review and meta-analysis of observational studies (the SOS project). Drug Saf. 2012;35(12):1127–46. DOI: 10.2165/11633470-000000000-00000.</p><p>Hochman J, Shah N. What Price Pain Relief? Circulation. 2006;113(25):2868–70. DOI: http://dx.doi.org/10.1161%2FCIRCULATIONAHA.106.634386.</p><p>Hermann M. Cardiovascular risk associated with nonsteroidal anti-inflammatory drugs. Curr Rheumatol Rep. 2009;11(1):31–5. DOI: http://dx.doi.org/10.1007%2Fs11926-009-0005-5.</p><p>Trelle S, Reichenbach S, Wandel S et al. Cardiovascular safety of non-steroidal anti-inflammatory drugs: network meta-analysis. BMJ. 2011;342:c7086. DOI: 10.1136/bmj.c7086.</p><p>McGettigan P, Henry D. Cardiovascular risk with non-steroidal anti-inflammatory drugs: systematic review of population-based controlled observational studies. PLoS Med. 2011;8(9):e1001098. DOI: 10.1371/journal.pmed.1001098. Epub 2011 Sep 27.</p><p>Varas-Lorenzo C, Riera-Guardia N, Calingaert B et al. Myocardial infarction and individual nonsteroidal anti-inflammatory drugs meta-analysis of observational studies. Pharmacoepidemiolog Drug Saf. 2013;22:559–70. DOI: 10.1002/pds.3437.</p></div><br />


Для цитирования:


Каратеев А.Е. Целекоксиб: оценка эффективности и безопасности во втором десятилетии XXI века. Современная ревматология. 2013;7(4):54-61. https://doi.org/10.14412/1996-7012-2013-2439

For citation:


Karateev A.E. Celecoxib: evaluation of its efficacy and safety in the second decade of the 21st century. Modern Rheumatology Journal. 2013;7(4):54-61. (In Russ.) https://doi.org/10.14412/1996-7012-2013-2439

Просмотров: 860


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1996-7012 (Print)
ISSN 2310-158X (Online)